Are you Dr. Bhalla?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-1782
Summary
- Dr. Kapil Bhalla, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Georgia. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1980 - 1983
New York Medical College at St Michael's Medical CenterResidency, Internal Medicine, 1977 - 1980- St Michael's Medical CenterInternship, Transitional Year, 1976 - 1977
Maulana Azad Medical CollegeClass of 1976
Certifications & Licensure
NY State Medical License 1980 - Present
FL State Medical License 1999 - 2025
TX State Medical License 2017 - 2025
GA State Medical License 1995 - 2013
KS State Medical License Active through 2013
SC State Medical License 1989 - 2013
NJ State Medical License 1977 - 1993- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
Publications & Presentations
PubMed
- Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.Warren Fiskus, Christopher P Mill, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju
Blood. 2024-11-19 - Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the internatio...Branko Cuglievan, Hagop Kantarjian, Jeffrey E Rubnitz, Todd M Cooper, C Michel Zwaan
Leukemia. 2024-10-01 - 8 citationsBRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.Warren Fiskus, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan
Blood. 2024-05-16
Press Mentions
Two Muslim Doctors Become First Donors of Plasma in Indore for Trial Treatment of Covid-19 PatientsApril 27th, 2020
MD Anderson Research Highlights AACR 2024 Special EditionApril 6th, 2024
